Table 2.
Vitamin K antagonist use and renal function decline
| Mean decline in eGFR (mL/min/1.73 m2/year) | −1.45 (95%CI −1.80 to −1.10)
|
|---|---|
| Change in decline in eGFR mL/min/1.73m2 per year (95% CI) | |
| Vitamin K antagonist non-users | Reference |
| Vitamin K antagonist users, crude | 0.43 (−0.74 to 1.60) |
| Vitamin K antagonist users, adjusteda | −0.09 (−1.29 to 1.11) |
| Vitamin K antagonist users, adjustedb | −0.09 (−1.32 to 1.13) |
Notes:
a
Adjusted for age, sex, race, diabetes mellitus, hypertension, cardiovascular disease, malignancy, gastro-intestinal problems, antiplatelet drug use, and primary kidney disease;
b
additionally adjusted for hemoglobin levels.
Abbreviation: eGFR, estimated glomerular filtration rate.